Related references
Note: Only part of the references are listed.Transformations of marginal zone lymphomas and lymphoplasmacytic lymphomas: Report from the 2021 SH/EAHP Workshop
James R. Cook et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)
Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study
Ilja Kalashnikov et al.
BLOOD CANCER JOURNAL (2023)
Marginal-Zone Lymphomas
Davide Rossi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation
Gabriela Bastidas-Mora et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Elias Campo et al.
BLOOD (2022)
Primary intracranial marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the lateral ventricle: Case report and review of pathogenesis
Sabastian Hajtovic et al.
Surgical Neurology International (2022)
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Peter Malfertheiner et al.
GUT (2022)
Chemotherapy is an efficient treatment in primary CNS MALT lymphoma
Clement Desjardins et al.
JOURNAL OF NEURO-ONCOLOGY (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio et al.
LEUKEMIA (2022)
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
Michael Herold et al.
HEMASPHERE (2022)
Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases
Yutaka Tsutsumi et al.
MOLECULAR AND CLINICAL ONCOLOGY (2021)
Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study
Jennifer A. Woyach et al.
BLOOD (2021)
Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis
Kyoungwon Jung et al.
HELICOBACTER (2021)
Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy
Hidehiko Takigawa et al.
GASTRIC CANCER (2021)
Natural history of MZ B cells
David Nemazee
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato et al.
LANCET (2021)
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial
Peter Hoskin et al.
LANCET ONCOLOGY (2021)
Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients
Joachim Yahalom et al.
BLOOD ADVANCES (2021)
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Stephen Opat et al.
CLINICAL CANCER RESEARCH (2021)
Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15
Michael P. MacManus et al.
EUROPEAN JOURNAL OF CANCER (2021)
PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38)
M. C. Pirosa et al.
HEMATOLOGICAL ONCOLOGY (2021)
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
Laurie Helen Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways
Marco Magistri et al.
CANCER RESEARCH COMMUNICATIONS (2021)
A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas
Barbara Vannata et al.
HEMATOLOGICAL ONCOLOGY (2021)
Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function*
Jillian R. Gunther et al.
LEUKEMIA & LYMPHOMA (2020)
Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma A Potential Diagnostic Pitfall
Caoimhe Egan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches
Shigeo Nakamura et al.
PATHOLOGY (2020)
Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients
Khaled Elsayad et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2020)
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Zucca et al.
ANNALS OF ONCOLOGY (2020)
90Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study
Ginevra Lolli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement
Andrew J. Sunderland et al.
CANCER MEDICINE (2020)
Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
Caron A. Jacobson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Update: the investigation and management of follicular lymphoma
Christopher McNamara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients
Alice Morigi et al.
HEMATOLOGICAL ONCOLOGY (2020)
Radiotherapy in Early-stage Gastric MALT Improved Survival Without Increased Cardiac Death
Alexandra N. De Leo et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V)
Nilima Parry-Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy et al.
BLOOD ADVANCES (2020)
Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance
Morton Coleman et al.
BLOOD (2020)
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
David J. Andorsky et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
Chelsea C. Pinnix et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Transformation of a splenic marginal zone lymphoma into classic Hodgkin lymphoma
Thomas Menter et al.
JOURNAL OF CLINICAL PATHOLOGY (2019)
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study
Stefano Luminari et al.
BLOOD (2019)
RITUXIMAB ALONE (R) VERSUS RITUXIMAB PLUS BENDAMUSTINE (BR) FOR SPLENIC (SMZL) AND NODAL MARGINAL ZONE LYMPHOMA (NMZL)
A.J. Olszewski et al.
HEMATOLOGICAL ONCOLOGY (2019)
FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY
S. Ferrero et al.
HEMATOLOGICAL ONCOLOGY (2019)
Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna
Barbara Kiesewetter et al.
HEMATOLOGICAL ONCOLOGY (2019)
Assessment of Late Toxicities of Liver and Kidney after Definitive Radiotherapy for Gastric MALT Lymphoma
S. Taguchi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Analysis of Chronic Renal Failure Following Radiotherapy for Gastric/Duodenal Mucosa-associated Lymphoid Tissue Lymphoma at a Single Institution
T. Katsuta et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma
Adam J. Olszewski et al.
BLOOD (2019)
MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications
Ruben A. L. de Groen et al.
HAEMATOLOGICA (2019)
Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
Sung Yong Oh et al.
CANCER COMMUNICATIONS (2019)
Marginal Zone Lymphoma: State-of-the-Art Treatment
Ariel Sindel et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma
Christian Grommes et al.
NEURO-ONCOLOGY (2019)
First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas
Roberto Castelli et al.
MEDICAL ONCOLOGY (2018)
Immunoglobulin G4 (IgG4)-Positive Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma and Idiopathic Orbital Inflammation
Eun Jung Sohn et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2018)
Lymphomas in IgG4-related disease: clinicopathologic features in a Western population
Jacob R. Bledsoe et al.
VIRCHOWS ARCHIV (2018)
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R. Willemze et al.
ANNALS OF ONCOLOGY (2018)
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
W. Jurczak et al.
ANNALS OF ONCOLOGY (2018)
Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
Christina Kalpadakis et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
Christina Kalpadakis et al.
BLOOD (2018)
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO
Irit Avivi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Extranodal Marginal Zone Lymphoma of the Central Nervous System
Adanma Ayanambakkam et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Prevalence and Implications of Bone Marrow Involvement in Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Sang Il Choi et al.
GUT AND LIVER (2018)
Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis
Dai Chihara et al.
Oncotarget (2018)
Meningeal marginal zone B-cell lymphoma: The meningioma trap
Alexandre Villeneuve et al.
EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES (2018)
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
Nathan M. Denlinger et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).
Mathias J. Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study
Emilio Iannitto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution
Juan Pablo Alderuccio et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma
Shunan Qi et al.
BLOOD ADVANCES (2018)
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma
Barbara Kiesewetter et al.
BLOOD (2017)
Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies
Alexandra Traverse-Glehen et al.
LEUKEMIA & LYMPHOMA (2017)
Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences
Macarena I. de la Fuente et al.
LEUKEMIA & LYMPHOMA (2017)
LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01).
A. Salar et al.
HEMATOLOGICAL ONCOLOGY (2017)
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)
M. Herold et al.
HEMATOLOGICAL ONCOLOGY (2017)
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
Emanuele Zucca et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma
Peter Martin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma
S. Teckie et al.
ANNALS OF ONCOLOGY (2017)
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy et al.
BLOOD (2017)
Splenic marginal zone lymphoma
Miguel A. Piris et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Transformation of marginal zone lymphoma (and association with other lymphomas)
Carla Casulo et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Splenic irradiation for splenomegaly: A systematic review
Nicholas G. Zaorsky et al.
CANCER TREATMENT REVIEWS (2017)
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection
Luca Arcaini et al.
BLOOD (2016)
Optimizing therapy for nodal marginal zone lymphoma
Catherine Thieblemont et al.
BLOOD (2016)
The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance
Emanuele Zucca et al.
BLOOD (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era
Salvatore Perrone et al.
LEUKEMIA RESEARCH (2016)
The genetic landscape of dural marginal zone lymphomas
Karthik A. Ganapathi et al.
ONCOTARGET (2016)
Underutilization of radiation therapy in early-stage marginal zone lymphoma negatively impacts overall survival
Diane C. Ling et al.
PRACTICAL RADIATION ONCOLOGY (2016)
Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network
A. Smith et al.
BRITISH JOURNAL OF CANCER (2015)
Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group
Lena Specht et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder?
Philip M. Kluin et al.
JOURNAL OF PATHOLOGY (2015)
Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with a long term follow-up
Agnes Ruskone-Fourmestraux et al.
RADIOTHERAPY AND ONCOLOGY (2015)
77-YEAR-OLD WOMAN WITH A DURAL-BASED MASS
Ross A. Okimoto et al.
BRAIN PATHOLOGY (2015)
Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis
Giorgio Treglia et al.
HEMATOLOGICAL ONCOLOGY (2015)
KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype
A. Clipson et al.
LEUKEMIA (2015)
Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)
Barbara Kiesewetter et al.
ANNALS OF HEMATOLOGY (2014)
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi
L. Arcaini et al.
ANNALS OF ONCOLOGY (2014)
Diagnosis of Splenic B-Cell Lymphomas in the Bone Marrow A Review of Histopathologic, Immunophenotypic, and Genetic Findings
Amir Behdad et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn et al.
BLOOD (2014)
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
Annarita Conconi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Helicobacter pylori infection in gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma: a re-evaluation
Larissa Sena Teixeira Mendes et al.
GUT (2014)
Efficacy of 90Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma
Anna Vanazzi et al.
HEMATOLOGICAL ONCOLOGY (2014)
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non- inferiority trial
Peter J. Hoskin et al.
LANCET ONCOLOGY (2014)
Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment
Julien Lenglet et al.
LEUKEMIA & LYMPHOMA (2014)
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial
Antonio Salar et al.
LANCET HAEMATOLOGY (2014)
Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Zucca et al.
ANNALS OF ONCOLOGY (2013)
Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature
Barbara Kiesewetter et al.
BLOOD (2013)
Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice
Christiane Copie-Bergman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review
Michiel van den Brand et al.
HAEMATOLOGICA (2013)
Eradication Therapy in Helicobacter pylori-negative, Gastric Low-grade Mucosa–associated Lymphoid Tissue Lymphoma Patients
Angelo Zullo et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study
Emanuele Zucca et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Primary cutaneous marginal zone B-cell lymphoma: Response to treatment and disease-free survival in a series of 137 patients
Octavio Servitje et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study
Hye Jin Kang et al.
ANNALS OF HEMATOLOGY (2012)
Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial
Andres J. M. Ferreri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development
Davide Rossi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma
Mark J. Kiel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications
V. Bikos et al.
LEUKEMIA (2012)
An Integrated Genomic and Expression Analysis of 7q Deletion in Splenic Marginal Zone Lymphoma
A. James Watkins et al.
PLOS ONE (2012)
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
A. Conconi et al.
ANNALS OF ONCOLOGY (2011)
EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT
A. Ruskone -Fourmestraux et al.
GUT (2011)
Genomic profiles of MALT lymphomas: variability across anatomical sites
Ivo Kwee et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
PALLIATION BY LOW-DOSE LOCAL RADIATION THERAPY FOR INDOLENT NON-HODGKIN LYMPHOMA
Elisa K. Chan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Mark Kirschbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Marginal zone lymphomas involving meningeal dura: possible link to IgG4-related diseases
Girish Venkataraman et al.
MODERN PATHOLOGY (2011)
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial
Lisa Lowry et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Central nervous system manifestations of marginal zone B-cell lymphoma
Soley Bayraktar et al.
ANNALS OF HEMATOLOGY (2010)
First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors
Tae Min Kim et al.
CANCER SCIENCE (2010)
Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma
Sven de Vos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma
Nancy J. Senff et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study
L. G. Capelle et al.
EUROPEAN JOURNAL OF CANCER (2008)
IgG4-producing marginal zone B-cell lymphoma
Yasuharu Sato et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Low-dose and limited-volume radiotherapy alone for primary dural marginal zone lymphoma: Treatment approach and review of published data
Dev R. Puri et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?
Alexandra Traverse-Glehen et al.
BLOOD (2008)
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
E. Matutes et al.
LEUKEMIA (2008)
MicroRNA losses in the frequently deleted region of 7q in SMZL
E. Ruiz-Ballesteros et al.
LEUKEMIA (2007)
MALT lymphoma in patients with autoimmune diseases:: a comparative analysis of characteristics and clinical course
S. Woehrer et al.
LEUKEMIA (2007)
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)
Youn H. Kim et al.
BLOOD (2007)
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: A multicenter prospective trial
Andres J. M. Ferreri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Primary dural lymphomas: A clinicopathologic study of treatment and outcome in eight patients
Fabio M. Iwamoto et al.
NEUROLOGY (2006)
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication
T Wündisch et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: A primary low-grade CNS lymphoma that mimics meningioma
PH Tu et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?
C Copie-Bergman et al.
ANNALS OF ONCOLOGY (2005)
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunoproliferative small intestinal disease associated with Campylobacter jejuni
M Lecuit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series
W Fischbach et al.
GUT (2004)
Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma
C Copie-Bergman et al.
GUT (2003)
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
A Conconi et al.
BLOOD (2003)
Paris staging system for primary gastrointestinal lymphomas
A Ruskoné-Fourmestraux et al.
GUT (2003)
High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma
HT Ye et al.
BLOOD (2003)
Small b-cell lymphoma presenting as diffuse dural thickening with cranial neuropathies
M Estevez et al.
JOURNAL OF NEURO-ONCOLOGY (2002)
Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori
W Fischbach et al.
LANCET (2002)
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H-pylori eradication
HX Liu et al.
GASTROENTEROLOGY (2002)
Stage I and II malt lymphoma: Results of treatment with radiotherapy
RW Tsang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy
HX Liu et al.
LANCET (2001)
Share Paper
